Neuroprotection Through Hypothermia and Anesthetics

Introduction: Biologic Basis of Neuroprotection

• At normal body temperature, roughly 60% of cerebral oxygen consumption supports neuronal electrophysiologic activity and is reflected in electroencephalography (EEG) patterns. The remaining approximately 40% is allocated to baseline cellular homeostasis, including maintenance of ion gradients and structural integrity.
• Cerebral blood flow (CBF) remains stable across a wide range of perfusion pressures, averaging about 50 mL/100 g/min. Flow below 20 mL/100 g/min typically produces an isoelectric EEG, and rates below 10 mL/100 g/min lead to loss of cellular integrity and irreversible injury.^1,2 (See “Cerebral autoregulation” Summary: Link). Cerebral injury may be focal or global, depending on the extent of substrate interruption.
• Neuroprotection focuses on supporting the brain under conditions of reduced blood flow or metabolic stress. Hypothermia and anesthetic agents can slow metabolic demand, reduce adenosine triphosphate (ATP) consumption, and attenuate excitotoxic, oxidative, and inflammatory cascades after ischemia.1 Despite compelling mechanisms, most evidence for neuroprotection remains preclinical, and consistent improvements in human outcomes are yet to be demonstrated.^1-4

Hypothermia as a Neuroprotective Strategy

• By decreasing CMRO_₂ by roughly 6–7% per °C, cooling slows ATP depletion, reduces glutamate release, and blunts oxidative and inflammatory cascades that drive secondary brain injury.¹
• Hypothermia remains one of the most biologically plausible and extensively studied neuroprotective interventions in various settings.
• Cardiac surgery: In aortic arch repair requiring circulatory arrest, hypothermia has long been essential to extending the brain’s tolerance for low-flow states. Deep hypothermia, as low as 17 °C, reduces CMRO₂ to approximately 7% of that at 37 °C and extends safe ischemic time to more than 30 minutes. (Figure 1) More recent data show that moderate hypothermia combined with antegrade cerebral perfusion achieves similar neurologic outcomes with fewer systemic complications.⁹

• Intracranial surgery: The IHAST trial found no evidence that mild hypothermia (33 °C) improved outcomes during surgical clipping of ruptured intracranial aneurysms (1001 patients in 30 centers).⁸
• Neonatal hypoxic–ischemic encephalopathy: Large randomized trials show that cooling to about 33.5 °C for 72 hours significantly reduces death or severe disability, which established therapeutic hypothermia as the standard of care in this population.⁵
• Postcardiac arrest care: While early trials supported hypothermia (32–34 °C), more recent large studies, including the TTM2 (Targeted Temperature Management-2 trial), show no difference in outcomes between 33 °C and controlled normothermia with fever avoidance.6 These findings are reflected in the most recent 2025 American Heart Association updated guidelines, which emphasize active temperature control and prevention of hyperthermia over routine deep cooling.⁷
• Severe traumatic brain injury (TBI): Prophylactic cooling has not improved outcomes and may increase complications. Current guidelines recommend using hypothermia only for refractory intracranial hypertension, as part of a carefully titrated ICP-management strategy, that includes slow, controlled rewarming to avoid rebound ICP rises.^3,10
• Overall, hypothermia provides robust mechanistic neuroprotection, but clinical benefit depends heavily on timing, depth and duration of cooling, rewarming rates, and meticulous support of cerebral perfusion and systemic physiology in the appropriate clinical context.

The Role of Anesthetic Agents in Neuroprotection

Effects on CMRO₂, CBF, and autoregulation

• Several anesthetic drugs can mimic some metabolic effects of hypothermia by reducing neuronal activity and CMRO₂. Their diverse effects on CMRO₂, blood flow dynamics and neuroprotective roles are summarized in Table 1.
• Intravenous anesthetics, such as propofol and barbiturates, may provide neuroprotection by reducing cerebral metabolic demand and mitigating excitotoxic and oxidative injury.2 Their parallel reductions in CMRO₂ and CBF help maintain flow–metabolism coupling. At higher doses, they can also induce burst suppression, a state of profound metabolic suppression that clinically may confer benefit in refractory intracranial hypertension and status epilepticus.^3,4 Consistent evidence to support their neuroprotective benefit across broader clinical contexts and during the intraoperative phase remains elusive.^2-4
• Volatile anesthetic agents (e.g., sevoflurane, isoflurane, desflurane) have several biologically plausible neuroprotective mechanisms, including reduced CMRO₂, enhanced inhibitory signaling, and attenuation of excitotoxic and inflammatory pathways. However, through dose-dependent cerebral vasodilation, they can uncouple CBF from metabolic demand. This may offset their protective mechanisms in patients with high intracranial elastance (e.g., brain swelling), in which the intracranial compartment has reduced capacity to accommodate volume changes without significant pressure increases. Furthermore, their neuroprotective profile remains theoretical and unsupported by consistent outcome data.²

Burst Suppression in Clinical Practice

• Burst suppression reflects a state of profound metabolic downregulation, which arises when cerebral energy supply is insufficient to sustain continuous synaptic activity.^3,4 It can be induced intentionally with high-dose intravenous anesthetics or deep hypothermia, or appear spontaneously after severe hypoxic–ischemic injury.
• Clinically, therapeutic burst suppression has very limited indications: it has utility in refractory intracranial hypertension or status epilepticus where reducing CMRO₂ and suppressing cortical activity may help control ICP or halt seizures.^3,10 Although these applications can be effective for physiologic control, consistent evidence for improved long-term neurological outcomes remains elusive.¹⁰
• Spontaneous or persistent burst suppression after cardiac arrest typically indicates severe cortical injury and implies poor prognostic significance⁷ (Figure 2). Burst suppression is also a useful monitoring marker, which can help confirm adequate cerebral cooling during deep hypothermic circulatory arrest (DHCA) or alert to excessive anesthetic depth.⁹
• Overall, while burst suppression has important therapeutic and diagnostic roles, its benefits are context-dependent, and its induction requires careful hemodynamic support to avoid compromising cerebral perfusion.

Anesthetic Neuroprotective Management Strategies

• Cardio-thoracic surgery: A common strategy is volatile anesthesia at modest minimum alveolar concentration levels or propofol-based total intravenous anesthesia, avoiding deep anesthetic-induced hypotension or excessive burst suppression except when required (e.g., DHCA).^2,9 Careful titration guided by EEG helps maintain adequate depth while minimizing unnecessary suppression that could impair immediate neurologic assessment.
• Cerebral aneurysm surgery: The IHAST trial showed that mild hypothermia did not improve outcomes compared with normothermia, but neurophysiologically informed anesthetic management (propofol-dominant regimens and avoidance of extreme burst suppression during critical testing phases) remains important for optimizing cerebral perfusion and enabling rapid postoperative assessment.^2,8
• Postcardiac arrest: Targeted temperature management protocols usually include propofol, midazolam, or other sedatives to prevent shivering and maintain comfort. The American Heart Association guidelines emphasize avoiding hyperthermia, individualized sedation titrated to clinical goals, and the overall post-cardiac arrest bundle (hemodynamics, ventilation, seizure control, and multimodal prognostication).⁷
• Severe TBI and other neurocritical care scenarios: Sedation strategies are integrated with targeted ICP, cerebral perfusion pressure, and oxygenation.³ Burst suppression and/or hypothermia are reserved for carefully selected, refractory cases, recognizing that any potential neuroprotective benefit must be weighed against hemodynamic instability, infections, and other systemic complications.^3,10